Dr. Manasanch on Outcomes With Elranatamab in Multiple Myeloma

Partner | Cancer Centers | <b>MD Anderson</b>

Elisabet E. Manasanch, MD, discusses outcomes seen with elranatamab in patients with relapsed or refractory multiple myeloma.

Elisabet E. Manasanch, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses outcomes seen with elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma.

Results from the phase 2 MagnetisMM-3 trial (NCT04649359) showed that among the 4 patients enrolled to the study who had received prior treatment with a BCMA-directed therapy, 3 of them still achieved a response with elranatamab, according to Manasanch. This provides further evidence that patients can receive previous treatment with a BCMA-targeted agent, such as belantamab mafodotin-blmf (Blenrep), and still respond to a subsequent BCMA-directed approach, Manasanch says.

Previously, it was not known whether utilizing a BCMA-directed approach after prior BCMA-directed therapy would lead to positive outcomes; however, it is becoming evident that these agents can be effectively sequenced, Manasanch concludes.